⇀ Investment Team

Pierre Moustial
Founding Partner (Paris)

Pierre is an experienced healthcare manager and deal maker.

He is the former CEO of Urgo and the former CEO of Fournier Pharma. He transformed Urgo into a global wound care giant, increasing revenue from €30m to €700m through a mix of innovation and accretive M&A. He scaled Fournier’s commercial capabilities in the United States and sold the business to Solvay for €1.3bn (excluding earnouts). Pierre began his career as a finance instructor and healthcare merchant banker at Paribas.

He is Chairman Emeritus of the Industry Association MedTech in France and is a graduate of HEC Paris.

Samuel Levy
Founding Partner (Paris)

Samuel is a physician entrepreneur.

He started his career as a management consultant at McKinsey & Company in New York before moving to Boston to attend Harvard Medical School. As a second-year medical student, Samuel co-founded Allurion Technologies and built a fully-integrated, global medical device company from the idea stage to commercialization in more than 30 countries.

Samuel is a graduate of Yale College (summa cum laude) and Harvard Medical School. He was a Fulbright Scholar to France at the Pasteur Institute.

Alex Slack
Founding Partner (San Francisco)

Alex is a healthcare specialist investor.

After starting his career as a management consultant at McKinsey & Company in Boston, he joined Maverick Capital’s healthcare team. Alex focused on long/short public equity and venture capital/cross-over investments, ultimately as Managing Director. Alex then joined Jackson Square Partners where he focused on high-conviction healthcare public equities and led the firm’s ESG activities.

Alex is a graduate of Harvard College (magna cum laude, Phi Beta Kappa).

Edoardo Fracchia
Partner (Paris)

Edoardo is a professional investor with more than 10 years in private equity.

He started his career at Idinvest focusing on minority equity deals and secondary transactions. Subsequently, Edoardo joined BlackFin Capital Partners where he led the execution of several deals and actively participated in portfolio management and value creation efforts. He then joined Eurazeo where he leveraged his expertise in deal origination and execution and enriched his sectorial knowledge through his involvement in several verticals (Medtech, financial services, TMT).

Edoardo graduated from ESCP, City University London and the University of Turin.

Nicolas Paulmier
Senior Investment Advisor (Paris)

Nicolas is a decorated private equity investor with more than 30 years of experience.

He started his career doing R&D at Sanofi and research at the Pasteur Institute and Harvard University (as a Tower Fellow). Nicolas transitioned from research to the Private Equity industry holding senior positions first at Electra and then at Cinven. Over more than twenty years, Nicolas led the French team and was part of the Investment Committee and Steering Committee.

Nicolas holds an MBA from INSEAD as well as an MSc in Molecular Biology from ENS Paris.

Antoine Héral
Senior Advisor (Florence)

Antoine is a healthtech operator and veteran of five successful healthcare LBOs spanning Medtech, healthcare software, and healthcare services. Antoine graduated from ESSEC business school in France. He started his career at Procter & Gamble in Japan and then in France. He then spent 5 years at the Boston Consulting Group as part of the consumer goods and healthcare practices before dedicating 100% of his professional time to investing in and operating fast-growing healthcare businesses.

Charles Cornevin
Principal (Paris)

Prior to joining Lauxera Capital Partners, Charles Cornevin was a Senior Associate at Eurazeo where he focused on healthcare buyouts. Charles joined Eurazeo in 2017 as an Analyst after several experiences in M&A and Private Equity (Rothschild and Hudson Advisors / Lone Star Funds in Munich, Dublin and London).

Charles started his career as a generalist investor within the Eurazeo Mid-Cap team and has participated in the monitoring of the following investments: Odealim (incl. exit), Redspher, Dessange, and the Rosa Group. He then launched the Eurazeo Healthcare-dedicated strategy from scratch and completed two investments in 2021: Novair Group and PSIH.

Charles graduated from Paris Dauphine University with a Masters in Corporate Finance and Financial Engineering.

Victoire

Victoire Ribert
Associate (Paris)

Victoire joined Lauxera Capital Partners’ investment team as an Associate in April 2023.

Prior to joining Lauxera, Victoire worked in Investment Banking at mid-cap advisory firm Scalene Partners, where she contributed to multiple buyout operations in various sectors, working closely with entrepreneurs and investment funds. She also completed several internships in M&A and ECM at Société Générale, and in Private Equity at HIG Capital.

Victoire graduated from Sciences Po Paris with a Masters in Finance and Strategy.

Alessandra Petiot
Associate (Paris)

Alessandra joined Lauxera Capital Partners as an Investment Analyst in January 2022.

Prior to joining the Fund, Alessandra had several internship experiences between Paris and London in Investment Banking at Lazard, HSBC and J.P.Morgan and in Private Equity at Eurazeo.
At Eurazeo, Alessandra worked in the Mid-Cap generalist team, where she participated in the analysis of several buyout investment opportunities.

Alessandra graduated from Paris Dauphine University with a Master in Financial and Economic Engineering.

Alexia Renaut
Analyst (Paris)

Prior to joining Lauxera Capital Partners as an Investment Analyst in January 2023, Alexia completed two internships at Edmond de Rothschild.

Her first role was in the business development team of the Private Bank where she worked for six months on the analysis of buy and build platforms in the healthcare sector. Subsequently, she worked for the midcap M&A team where she was involved in the Simago LBO.

Alexia graduated from EM Lyon business school with a Master’s degree in Management and Corporate Finance.

Lise Bettoun
Head of Operations (Paris)

Lise began her career in Molecular Biology research in various institutes before joining Sanofi at the Research and Development (R&D) department. Lise then took her R&D experience to CIMI (Immunology and Infectious Diseases center) in Paris where she conducted research in Cell Therapies in Immunology. Subsequently, she acted as a consultant in Healthcare & Life Sciences at EY before joining Lauxera as the Head of Operations in June 2021.

Lise earned a Doctorate in Pharmacy and a Specialised Master in Innovative Therapies and Biotechnologies from the Université Paris-Sud (Paris XI) before graduating from the ESCP Business School with a Master in Pharmaceutical Management and Biotechnology in 2019.

Alix De Benedetti
Investor Relations Manager (Paris)

Alix began her career at YOOK Net-a-Porter in Milan in the Marketing team. She then joined Cowen LLC., in New York, as an Investment Banking analyst and subsequently moved into the Chief of Staff team, with an Investment Relations mandate. She then moved back to Europe and joined Sogefi S.p.A in the M&A and Finance team, before joining Lauxera in September 2022.

Alix is finalising an Executive MBA from Università Bocconi after having earned a Bachelor’s degree in Business and Finance at Università Cattolica in Milan.

Delphine Leduc
Executive Assistant (Paris)

Delphine started her career in Montreal at an agency specialized in event staffing. Over the course of 10 years, she held various roles including head of recruitment, project manager, and director of operations.

Delphine received her degree from Paris 8 University and is a certified Project Management Professional (PMP).

⇀ Special Advisors

Elsy Boglioli

Denis Delval

Jeffrey Flier

Taylor Harris

Stéphane Mulard

Julie Jonte

Paris
41 Avenue de Friedland
75008 Paris
France

San Francisco
129 Miller Ave, Ste 824
Mill Valley, CA 94941
USA

Contact
contact@lauxera.com

© Lauxera Capital Partners | Legal mentions | Site by Etzi.co

Elsy is an experienced healthcare operator and strategist.

Elsy began her career at The Boston Consulting Group where she served a
variety of international healthcare clients over ten years as Partner and
Managing Director. Subsequently, Elsy joined Cellectis, an oncology-focused
cell therapy company as Chief Operating Officer. She now leads a healthtech
advisory firm called Bio-Up that she founded in 2019. Elsy serves on the board
of directors of a number of biotech and healthtech companies including
GenSight, NovaDiscovery, and Metafora Biosystems.

Elsy graduated with a degree in engineering from the Ecole Polytechnique as
well as a degree from the Universitat Pompeu Fabra and a degree in
immuno-oncology from the École des Sciences du Cancer – Institut Gustave
Roussy.

Denis is an experienced healthcare operator.

A graduate of ESSEC and INSEAD business schools with a PhD in Pharmacy,
Denis has a deep understanding of the pharmaceutical industry. He has held
important marketing, sales, and strategy positions in France, Europe, and
worldwide and has managed international partnerships within various
pharmaceutical groups (Bayer, Fournier Pharma, ALK). In 2006, he was
appointed General Manager of ALK France. In 2012, he also became Senior
Vice President of the Danish pharmaceutical company specialized in allergy
immunotherapy treatments. Since the end of 2017, he is the Chairman and CEO of
LFB, a biopharmaceutical company specialized in plasma-derived and
recombinant proteins used to treat severe and rare diseases.

Denis lectures at ESSEC business school and was also Chairman of Lecrip.org,
a healthcare think tank.

Jeff is an American physician, researcher, and former Dean of Harvard Medical
School.

Jeffrey S. Flier, M.D., is the Higginson Professor of Physiology and Medicine at
Harvard Medical School (HMS) and Distinguished Service Professor at Harvard
University. He received his M.D. from Mount Sinai School of Medicine in 1972
with the Elster Award for Highest Academic Standing. Following residency
training in internal medicine at Mount Sinai Hospital (1972–1974) and research
training as a Clinical Associate at the National Institutes of Health, Jeff joined
the Faculty of Medicine at HMS and Beth Israel Hospital as Chief of the
Diabetes Unit in 1978. He was later named chief of the hospital’s Endocrine
Division and Vice Chairman of Research. From 2007–2016, Jeff served as the
21st Dean of the Faculty of Medicine at Harvard University. The author of over
200 scholarly papers and reviews, Jeff is one of the leading investigators and
authorities on the molecular causes of obesity and diabetes. His research has
produced major insights into the molecular mechanisms of insulin action and
insulin resistance in human disease, and the molecular pathophysiology of
obesity.

Jeff is an elected member of the Institutes of Medicine and a fellow of the
American Academy of Arts and Sciences. In 2003, he received the Edwin B.
Astwood Lecture Award from the Endocrine Society. The American Diabetes
Association has honored Jeff with the Eli Lilly Award, the Banting Medal in
2005 (the ADA’s highest scientific honor) and the Albert Renold Award for
outstanding achievements in the training of diabetes research scientists and
the facilitation of diabetes research. In 2011, he was awarded the Rolf Luft
Award for Metabolic Research from the Karolinska Institute in Sweden.

Taylor is a healthcare operator with a track record of scaling and leading
high-value, high-growth medtech and biotech companies.

Taylor began his career at JP Morgan as a healthcare investment banker and
equity research analyst focused on the medical device industry. After 12 years
at the firm, Taylor joined the medical device company Thoratec ultimately
serving as CFO. Thoratec marketed mechanical circulatory support products
for the treatment of heart failure patients. Following Thoratec’s acquisition by
St. Jude Medical for approximately $3.4 billion, Taylor joined Zeltiq as CFO.
Zeltiq revolutionized the body contouring, cash-pay medical aesthetics sector
and was subsequently acquired for approximately $2.4 billion by Allergan.
Following that acquisition, Taylor joined the biotech company MyoKardia as
CFO. MyoKardia pioneered a precision medicine approach to treating
cardiomyopathies and other forms of heart failure. Bristol Myers Squibb
acquired MyoKardia in a cash-based transaction valued at $13.1 billion.

Taylor graduated from the University of North Carolina at Chapel Hill as a
Morehead-Cain Scholar with a BA in Physics and Economics.

Stéphane is a professional investor with more than 20 years of experience in
private equity.

Stéphane joined the leading European private equity firm Chequers Capital
early in his career, ultimately becoming Partner and Managing Director.
During his time there, Stéphane was critical to Chequers’ expansion from
solely operating in France to expanding to Germany, Italy, and Spain, all while
driving assets under management to 2.5 Bn€.

Stéphane graduated from the École Polytechnique with a degree in
Engineering and then earned a Master of Science in Petroleum Economics
and Management from IFP.

As a biologist, I was CEO of Biopath-idf between 2011 and 2018, and I accompanied the growth of the medical laboratory from 22 to 78 millions in turnover before joining Unilabs France until December 2020. As a member of the French management committee in charge of sales, marketing and innovation in partnership with the Medical Department and Operations, I participated in many development projects and learned a lot about the medical diagnostics sector (biology, radiology and anatomopathology) in Europe.

Since 2021, I have been managing the PJP Investissements holding company and have been actively involved in the selection and monitoring of investments, both direct and via private equity funds, particularly in the healthcare sector.